Jaffer Ajani

58PUBLICATIONS
278CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsLiquid biopsiesGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (58)

|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

|Apr 19, 2026
Clinical Machine Learning Model for Predicting Pathological Complete Response in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma After Trimodality Therapy.

|Mar 04, 2026
Association of Blood Levels of Forever Plastics with Lung Cancer Mortality among Ever Smokers in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cohort Study.

Ehsan Irajizad, Johannes F Fahrmann, Ranran Wu

|Feb 06, 2026
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim

|Dec 03, 2025
Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons.

Jaffer A Ajani, Kaijun Wang, Georgios F Nikolaidis

|Oct 04, 2025
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis.

Jaffer A Ajani, Maria Alsina, Markus Moehler

Pageof 10

Frequent Collaborators

12 joint publications

Shumei Song

7 joint publications

Linghua Wang

6 joint publications

Kohei Shitara

5 joint publications

Funda Meric-Bernstam